3
Announcements
Trials
Browse
Landscape
Phase
Phase EARLY_PHASE1
1
Phase 3
1
Status
Not yet recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Classical hematology
1
Conditions
Venous Thrombosis
1
Venous Thromboembolism
1
Pulmonary Embolism
1
Neoplasms
1
Interventions
pembrolizumab
130
Carboplatin
127
Cisplatin
118
Paclitaxel
99
Gemcitabine
87
Specimen Handling
80
Magnetic Resonance Spectroscopy
80
Docetaxel
70
Dexamethasone
62
Cyclophosphamide
61
Pemetrexed
59
Capecitabine
56
Bevacizumab
56
durvalumab
52
Oxaliplatin
52
Fluorouracil
50
Doxorubicin
49
Radiotherapy
48
Leucovorin
45
Radiation
44
Rituximab
43
Lenalidomide
42
Vincristine
39
Etoposide
36
Nivolumab
34
atezolizumab
33
Letrozole
32
130-nm albumin-bound paclitaxel
32
Irinotecan
31
Prednisone
29
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
apixaban
×
90 days
×
Clear all
NCT07493304
2026-03-25
ROXI-CAT-II
Regeneron Pharmaceuticals
Phase 3
Not yet recruiting
1,600 enrolled